Comparison of FIGO 1988 and 2009 staging systems for endometrial carcinoma

详细信息    查看全文

• 作者：Melis Gultekin (1)
  Ferah Yildiz (1)
  Gokhan Ozyigit (1)
  Havva Beyaz (1)
  Mutlu Hayran (2)
  Faruk Kose (3)
  Kunter Yuce (4)
  Ali Ayhan (5)
  
• 关键词：Endometrial carcinoma ; FIGO ; Staging ; Prognosis
• 刊名：Medical Oncology
• 出版年：2012
• 出版时间：December 2012
• 年：2012
• 卷：29
• 期：4
• 页码：2955-2962
• 全文大小：313KB
• 参考文献：1. Cancer Committee Report to the General Assembly of FIGO. Classification and staging of malignant tumor in the female pelvis. Int J Gynaecol Obstet: The official organ of the international federation of gynaecology and obstetrics. 1971;9:172-.
  2. FIGO stages-1988 revision. Gynecol Oncol. 1989;35:125-27.
  3. Mariani A, Webb M, Keeney G, et al. Assessment of prognostic factors in stage IIIA endometrial cancer. Gynecol Oncol. 2002;86:38-4. CrossRef
  4. Tebeu PM, Popowski Y, Verkooijen HM, et al. Positive peritoneal cytology in early stage endometrial cancer does not influence prognosis. Br J Cancer. 2004;16:720-.
  5. Nelson G, Randall M, Sutton G, et al. FIGO stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes: analysis of treatment outcomes, prognostic variables, and failure patterns following adjuvant radiation therapy. Gynecol Oncol. 1999;75:211-. CrossRef
  6. Zaino RJ. FIGO staging of endometrial adenocarcinoma: a critical review and proposal. Int J Gynecol Pathol. 2009;28:1-. CrossRef
  7. Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet. 2009;105:109. CrossRef
  8. Atahan IL, Ozyar E, Yildiz F, et al. Vaginal high dose rate brachytherapy alone in patients with intermediate- to high-risk stage I endometrial carcinoma after radical surgery. Int J Gynecol Cancer. 2008;18:1294-. CrossRef
  9. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5-6. CrossRef
  10. Kucera H, Vavra N, Weghaupt K. Benefit of external irradiation in pathologic stage I endometrial carcinoma: a prospective clinical trial of 605 patients who received postoperative vaginal irradiation and additional pelvic irradiation in the presence of unfavorable prognostic factors. Gynecol Oncol. 1990;38:99-04. CrossRef
  11. Gatta G, Lasota M, Verfecchia A. Working Group. Survival of European women with gynaecological tumours during the period 1978-9. Eur J Cancer. 1998;34:2218-5. CrossRef
  12. Lewin SN, Herzog TJ, Barrena Medel NI, et al. Comparative performance of the 2009. International federation of gynecology and obstetrics-staging system for uterine corpus cancer. Obstet Gynecol. 2010;116:1141-. CrossRef
  13. Cooke EW, Pappas L, Gaffney DK. Does the revised international federation of gynecology and obstetrics staging system for endometrial cancer lead to increased discrimination in patient outcomes? Cancer. 2011;117:4231-. CrossRef
  14. Werner HMJ, Trovik J, Marcickiewicz J et al. Revision of FIGO surgical staging in 2009 for endometrial cancer validates to improve risk stratification. Gynecol Oncol;2011, doi:10.1016/j.ygyno.2011.11.008 .
  15. Abu-Rustum NR, Zhou Q, Iasonos A, et al. The revised 2009 FIGO staging system for endometrial cancer: should the 1988 FIGO stages IA and IB be altered? Int J Gynecol Cancer. 2011;21:511-. CrossRef
  16. Jordan LB, Al-Nafussi A. Clinicopathological study of the pattern and significance of cervical involvement in cases of endometrial adenocarcinoma. Int J Gynecol Cancer. 2002;12:42-. CrossRef
  17. Ayhan A, Taskiran C, Celik C, et al. The long-term survival of women with surgical stage II endometrioid type endometrial cancer. Gynecol Oncol. 2004;93:9-3. CrossRef
  18. Cragun JM, Havrilesky LJ, Calingaert B, et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol. 2005;23:3668-5. CrossRef
  19. Mariani A, Webb MJ, Galli L, Podratz KC. Potential therapeutic role of para-aortic lymphadenectomy in node-positive endometrial cancer. Gynecol Oncol. 2000;76:348-6. CrossRef
  20. Solhjem MC, Petersen IA, Haddock MG. Vaginal brachytherapy alone is sufficient adjuvant treatment of surgical stage I endometrial cancer. Int J Radiat Oncol Biol Phys. 2005;62:1379-4. CrossRef
  21. Horowitz NS, Peters WA III, Smith MR, et al. Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma. Obstet Gynecol. 2002;99:235-0. CrossRef
  22. Mariani A, Keeney GL, Aletti G, et al. Endometrial carcinoma: paraaortic dissemination. Gynecol Oncol. 2004;92:833-. CrossRef
  23. McMeekin DS, Lashbrook D, Gold M, et al. Analysis of FIGO Stage IIIc endometrial cancer patients. Gynecol Oncol. 2001;81:273-. CrossRef
  24. ASTEC study group, Kitchener H, Swart AM, et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC Trial): a randomised study. Lancet. 2009;373:125-6. CrossRef
  25. Connell PP, Rotmensch J, Waggoner S, Mundt AJ. The significance of adnexal involvement in endometrial carcinoma. Gynecol Oncol. 1999;74:74-. CrossRef
  26. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomized trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma. Lancet. 2000;355:1404-1. CrossRef
  27. Creutzberg CL, van Putten WL, Warlam-Rodenhuis CC, et al. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the postoperative radiation therapy in endometrial carcinoma trial. J Clin Oncol. 2004;22:1234-1. CrossRef
  
• 作者单位：Melis Gultekin (1)
  Ferah Yildiz (1)
  Gokhan Ozyigit (1)
  Havva Beyaz (1)
  Mutlu Hayran (2)
  Faruk Kose (3)
  Kunter Yuce (4)
  Ali Ayhan (5)
  
  1. Department of Radiation Oncology, Faculty of Medicine, Hacettepe University, 06100, Ankara, Turkey
  2. Department of Preventive Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
  3. Clinic of Gynecologic Oncology, Etlik Zubeyde Hanim Maternity and Women’s Health Teaching and Research Hospital, Ankara, Turkey
  4. Department of Obstetrics and Gynecology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
  5. Department of Obstetrics and Gynecology, Faculty of Medicine, Baskent University, Ankara, Turkey
  

文摘

The objective of this study was to compare FIGO 1988 and 2009 endometrial carcinoma staging systems in terms of patient distribution and efficacy in predicting prognosis in patients treated with surgery and adjuvant radiotherapy (RT). Medical records of 351 patients treated between 1994 and 2009 were retrospectively analyzed. Adjuvant RT was in the form of vaginal cuff brachytherapy (BRT) in patients with uterine confined disease and risk factors, whereas high-risk patients received risk-adapted external pelvic RT. The median follow-up time was 55?months (range, 2.5-33?months). Five-year overall (OS) and disease-free survival (DFS) for the entire group was 83 and 88%, respectively. Stage migration was observed in 188 (54%) patients. Stage migration generally did not cause any significant effect in OS and DFS rates. However, 5-year OS and DFS for stage I patients with positive peritoneal cytology was significantly lower than the other patients with negative cytology in FIGO 2009 system. The survival curves overlapped for stage IA, IB and II in the new staging system. On the other hand, the division of stage IIIC as IIIC1 and IIIC2 significantly affected the prognosis. Patients with stage IIIC2 tumor had 40% OS and 48% DFS rates compared to 69 and 66% in stage IIIC1 patients (p?=?0.002). The major improvement of FIGO 2009 seems to be the subclassification of stage IIIC disease into IIIC1 and IIIC2. The positivity of peritoneal cytology per se seems to have an influence in prognosis in our cohort. To withdraw the positive cytology from staging may mislead the prognosis estimation in these patients and lead to undertreatment.